Skip to ContentSkip to Navigation
How to find us prof. dr. M.N. (Marjolijn) Lub-de Hooge

Research interests

Prof. Dr. Marjolijn N. Lub-de Hooge

is a Hospital Pharmacist and professor at the department of Clinical Pharmacy and Pharmacology, and at the department of Nuclear Medicine and Molecular Imaging of the University Medical Center Groningen. She obtained her PhD on pharmaceutical aspects and molecular imaging of new receptor targeted drugs.

Her research mainly focuses on molecular imaging to support drug development and to optimize treatment of cancer patients with novel (targeted and immuno) therapies. She is an expert in the development, evaluation and translation of new radiopharmaceuticals and optical tracers to the clinical setting. And she is also involved in the subsequent clinical application of these new tracers for drug development, and treatment optimization: visualization of presence of drug target (patient selection), drug biodistribution (pharmacokinetics, optimal dosing, target saturation) and tumor status during treatment (early predictive biomarker, pharmacodynamics).




Development and evaluation of interleukin-2 derived radiotracers for PET imaging of T-cells in mice

Moleculaire beeldvorming met 89Zr-immunoPET in translationele studies op het gebied van immuuntherapie

Molecular imaging biomarkers for immune checkpoint inhibitor therapy

Molecular imaging in lymphoma beyond F-18-FDG-PET: understanding the biology and its implications for diagnostics and therapy

Molecular Imaging of PD-L1 Expression and Dynamics with the Adnectin-Based PET Tracer F-18-BMS-986192

PET/CT Imaging of Zr-89-N-sucDf-Pembrolizumab in Healthy Cynomolgus Monkeys

Preclinical PET imaging of bispecific antibody ERY974 targeting CD3 and glypican 3 reveals that tumor uptake correlates to T cell infiltrate

Probody therapeutic design of 89Zr-CX-072 promotes accumulation in PD-L1 expressing tumors compared to normal murine lymphoid tissue

The Biodistribution of a CD3 and EpCAM Bispecific T-Cell Engager Is Driven by the CD3 Arm

Zr-89-pembrolizumab biodistribution is influenced by PD-1-mediated uptake in lymphoid organs

Read more